Masseter Botox: jaw slimming and teeth grinding, cost and results

The masseter is one of the muscles that closes the jaw when you bite and chew.

When it enlarges — a condition clinics call masseter hypertrophy — it can add width to the lower face.

Masseter Botox is botulinum toxin injected into that muscle to reduce its activity.

Per the Botox Cosmetic label, botulinum toxin blocks the release of acetylcholine, the chemical that carries the nerve signal telling a muscle to contract, producing a partial, localized reduction in muscle activity that reverses slowly as the nerve endings reconnect.

One injection site serves two different goals.

The cosmetic goal is jaw slimming: shrinking enlarged masseter muscles so a wide or square lower face looks softer.

The functional goal is teeth grinding (bruxism) and clenching, where the aim is to reduce the muscle's biting force rather than to change the face's shape.

Neither use is approved in the United States.

Botox Cosmetic (onabotulinumtoxinA, from Allergan/AbbVie) is FDA-approved in adults for the temporary improvement in the appearance of moderate to severe frown lines, crow's feet, forehead lines and platysma bands.

The masseter is not on that list, and no US neurotoxin label includes the masseter, so the use is off-label.

Off-label means the FDA has approved the product but not that specific use; whether to use it this way is a decision to make with a licensed provider.

The trial evidence for slimming is recent and comes from AbbVie, Botox's maker.

In its phase 3 trial, 376 adults with marked or very marked masseter prominence received either 72 units of onabotulinumtoxinA or a placebo injection.

At day 90, 51.2% of the treated group had improved by at least 2 grades on the trial's masseter prominence scale, versus 2.2% on placebo.

Lower-face width shrank by a mean of 5.24 mm in the treated group versus 0.04 mm on placebo, and improvements were sustained through day 180.

A 2026 meta-analysis of 5 randomized placebo-controlled trials, pooling 536 participants, reached a similar conclusion with a caution: botulinum toxin improved masseter prominence and muscle thickness in the short term, but the evidence does not yet define an optimal dose or protocol.

For grinding, the evidence base is separate.

Botulinum toxin is not FDA-approved for TMJ disorders or teeth grinding; no US toxin label lists either.

Injections into the masseters have been shown in studies to reduce biting force and pain.

A 2024 umbrella review of 18 high-quality systematic reviews concluded that botulinum toxin reduces muscle-related (myogenous) TMD pain more than placebo but not more than standard treatments, carries a higher risk of adverse effects on muscle and bone, and should be the last treatment alternative.

The phase 3 trial studied a specific population: 376 adults whose masseter prominence was rated marked or very marked.

The 12-month phase 2 study enrolled 187 adults, and the 2026 meta-analysis pooled 536 participants across 5 trials.

Across its doses, the phase 2 study saw no clinically relevant changes in the jawbone or teeth.

The label describes the toxin's effect as a localized reduction in muscle activity, so if your lower-face width comes mainly from bone structure, fat or skin rather than the muscle, the treatment has less to act on.

A licensed provider can assess your own face and tell you how much of your lower-face width is muscular.

That assessment is the starting point for deciding whether the treatment makes sense for you.

The product's label sets limits that apply wherever it is injected.

Botox Cosmetic is contraindicated in anyone with a known hypersensitivity to any botulinum toxin product or to any ingredient in the formulation, and when there is an infection at the planned injection site.

The label warns that people with neuromuscular disorders — it names myasthenia gravis, Lambert-Eaton syndrome and ALS — may be at increased risk of clinically significant effects, and it advises caution in people with pre-existing cardiovascular disease or swallowing or breathing problems.

Pregnancy and breastfeeding are a gap rather than a warning: there are no adequate human data on Botox Cosmetic in pregnancy and no data on whether it passes into breast milk.

Safety in pregnancy and breastfeeding is therefore not established by studies — which makes both fair questions to raise with a licensed provider before booking.

Because the masseter is off-label, no US label gives a jaw dose — there is no official unit count for the masseter the way 20 units is the Botox Cosmetic label dose for frown lines.

The dose is the provider's to set, and the trials show what has been studied rather than a standard.

AbbVie's phase 3 trial used 72 units of onabotulinumtoxinA.

The 12-month phase 2 study tested doses of 24 to 96 units.

The 2026 meta-analysis found benefit at 48-unit and 72-unit regimens while concluding that the evidence is insufficient to define an optimal dose or protocol.

Figures from other toxin brands do not transfer.

In a retrospective series from a single Korean clinic, 121 patients with masseter hypertrophy were treated repeatedly with 100 to 140 units of Dysport per side, and the mean dose needed decreased as treatments continued.

Toxin units are product-specific: the Botox Cosmetic label and the Dysport label each state that their units cannot be compared to or converted into units of any other botulinum toxin product.

Price follows the units.

Toxins are typically priced per unit or per treatment area, so a masseter session scales with the number of units injected — at the same per-unit price, a jaw treatment built on a 72-unit trial regimen costs more than an area treated at a 20-unit label dose.

Per-unit prices are set provider by provider, and because toxin units are product-specific, a per-unit price for one brand is not comparable to another's.

We could not confirm a current national average fee for neuromodulator injections.

The practical step is to ask providers for their per-unit price and the dose they plan for you, so you compare quotes for the same work.

A 4-to-8-week window for visible slimming is not a figure we could trace to a trial or a label.

The studies we reviewed measured results at day 90, about three months after treatment, and that is the honest anchor.

What the trials measured: at day 90 in the phase 3 trial, 51.2% of the treated group had improved by at least 2 grades, lower-face width was down a mean of 5.24 mm versus 0.04 mm on placebo, and improvements were sustained through day 180.

The phase 2 study saw lower-face volume fall significantly versus placebo at day 90 of its 12-month follow-up.

Day 180 is the last point the published phase 3 results report, not a promise about when the effect stops.

Teeth-grinding effects run on a different clock.

A 2023 meta-analysis on bruxism found botulinum toxin effects in the masseters appear within 4 weeks, peak between 5 and 8 weeks and last up to 24 weeks, while oral splints showed a more enduring effect after 9 to 12 weeks.

No label gives a masseter re-treatment interval, because no label covers the use.

For reference, the Botox Cosmetic label says the safety and effectiveness of dosing more often than every 3 months has not been clinically evaluated.

In the Korean clinic series, average masseter thickness fell from 13.32 mm at baseline to 9.94 mm at the last visit across repeated treatments, and the mean dose needed decreased as the number of treatments increased — a single-clinic retrospective series, not a controlled trial.

The trials reported one dose-related finding worth knowing.

In the 12-month phase 2 study, a localized impact on the smile was reported in 4 subjects at the 96-unit dose — the highest tested — while no clinically relevant changes in the jawbone or teeth were seen across the study.

The phase 3 trial used 72 units.

Smile changes are therefore in the trial record at the highest dose studied, which makes them a fair question to put to any provider before treatment.

Jowls are the harder question.

Readers ask whether shrinking a muscle that adds width to the lower face can soften the jawline or make jowls more visible.

The studies we reviewed measured lower-face width and volume, not jowl position, so we cannot confirm or rule out an effect either way.

That is a question to raise in consultation, where a provider can look at your own anatomy rather than a trial average.

Because the product is the same one used for frown lines, the label's general warnings apply.

Injection itself can cause localized pain, swelling, redness, tenderness and bruising.

Adverse reactions generally occur within the first week and, while often transient, may last several months or longer.

The label also states that no definitive serious adverse event reports of distant spread of toxin effect have come from dermatologic use at the labeled cosmetic doses.

Those are labeled doses; the masseter use is off-label and sits outside the label's dose statements, which is part of why the boxed warning below belongs in the conversation.

The Botox Cosmetic label states that physicians administering it must understand the relevant neuromuscular and structural anatomy of the treated area.

For an off-label area there is no label injection map to follow, so that anatomy requirement is doing all the work — a fair basis for asking a provider where they trained for masseter injections and how often they do them.

The CDC advises getting botulinum toxin injections only from a licensed, trained provider using product from an authorized source, and cautions that the procedure carries risk even when the product is FDA-approved and injected correctly.

That caution is concrete: in April 2024 the FDA warned that counterfeit Botox had been given to consumers for cosmetic purposes in multiple states, injected by licensed and unlicensed individuals and in non-medical or unlicensed settings, with product apparently bought from unlicensed sources; federal law requires providers to buy prescription drugs only from authorized sources.

CDC's closed 2023-2024 investigation counted 17 people in nine states with harmful reactions after injections involving counterfeit or unverified botulinum toxin products or providers not following state requirements; 13 were hospitalized.

Two more checks are cheap.

Genuine Botox Cosmetic shows U.S. License number 1889 on the vial and carton, per the label, which instructs the provider not to use product when that number is missing or the tamper-evident features look broken.

And who may inject is regulated state by state: the trade association AmSpa describes injecting botulinum toxin as the practice of medicine, done by a physician, an independent-practice nurse practitioner or another licensed professional acting within their scope, under rules that vary by state.

It is reasonable to ask who will perform the injection and what license they hold.

None of these questions is awkward to ask, and a good provider will answer them without being pushed.

If the answers are vague, that itself is information.

A guide like this one can tell you what the label, the trials and the regulators say; only a licensed provider who has examined you can tell you whether masseter Botox makes sense for your face.